Screener / SEC EDGAR /CIK 0001001316 /10-K filed Feb 27, 2026, compared with Mar 3, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

TG Therapeutics, Inc. TGTX

Compare with peers Embed
SEC comment letters, last 20 years

9 reviews of TGTX's filings by SEC staff

UPLOAD and CORRESP
Reviews 9 latest letter Jan 12, 2015
Questions asked 21 each answered in the company's own letter
No closing letter 5 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 11 UPLOAD
  2. 2. Questions in them 21 numbered comments
  3. 3. Company replies 10 CORRESP
  4. 4. Reviews closed 4 of 9 closing letter

Half the closed reviews took 58 days or less from the first letter to the closing letter.

Form S-3

2015-01-12 to 2015-01-16 · 1 question · 1 letter from the SEC, 1 from the company
No closing letter
General
SEC asked
We note that that you have a pending confidential treatment request. We will not be in a position to accelerate the effectiveness of your registration statement until we have completed processing your confidential treatment request.
TGTX answered
(the “Company”), hereby requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 11:00 a.m. (ET) on January 20, 2015 or as soon as practicable thereafter, pursuant to

Rule 461 of the Securities Act of 1933, as amended.

The Company acknowledges that (i) should the Commission or the staff of the Commission, acting pursuant to delegated authority, declare the filing effective, such declaration does not foreclose the Commission from taking any action with respect to the filing; (ii) the action of the Commission or
Rest of the answer

the staff of the Commission, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the

Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and (iii) the Company may not assert the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Read in the reply

Form 10-K for the fiscal year ended December 31, 2012

2013-09-23 to 2013-11-20 · 5 questions · 2 letters from the SEC, 2 from the company
Review closed 2013-11-20
Intellectual Property and Patents, page 8
SEC asked (1)
Please revise your disclosure to identify the expected expiration date for the material patents underlying TGR-1202.
TGTX answered
The Company proposes to amend its disclosure in the following manner (the revised language is in italics):

Pursuant to our Collaboration Agreement with Rhizen Pharmaceuticals for TGR-1202, we have the exclusive commercial rights to a series of patents and patent applications in the U.S. and abroad. These patents and patent applications include composition of matter patents relating to the structure and mechanism of action for TGR-1202 as well as method of use patents which cover use of TGR-1202 in combination with various agents and for various therapeutic indications.

All patent
Rest of the answer

applications currently filed for TG-1202 are currently pending. Because any potential date for regulatory approval is currently unknown we cannot predict the expected expiration date, and it is possible that the life of these patents following regulatory approval will be minimal.

Atlanta •

Brussels • Charlotte • Dallas • Los Angeles • New York • Research Triangle • Silicon Valley •

Ventura County • Washington, D.C.

Read in the reply
In its next report

First report after the company's reply of Oct 1, 2013: 10-Q filed Nov 14, 2013 ↗, against the 10-Q filed Aug 9, 2013 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Licensing Agreements and Collaborations, page 10
SEC asked (2)
Please revise your disclosure to include a discussion of the material terms of your collaboration and license agreements, as follows: For your license agreement with LFB Biotechnologies, GTC Biotherapeutics, and LFB/GTC LLC:  percentage range of royalties (within a ten-percent range, e.g., “10-20%,” “single digits”); and  termination provisions. For your sublicense agreement with Ildong Pharmaceutical Co.
Rest of the question

Ltd.:  aggregate milestone payments;  percentage range of royalties; and For your collaboration agreement with Rhizen Pharmaceuticals, S.A.:

TGTX answered
regarding the Company’s license agreement with LFB Biotechnologies, GTC Biotherapeutics, and LFB/GTC LLC in the following manner, (the revised language is in italics) but believes that the termination provision has been sufficiently addressed in the last sentence below, and due to the lack of a starting point to calculate the expiration date (either expiration of the patent, which has not yet been granted, or first commercial sale, of which there have been none to date) we cannot clarify the discussion any further:

TG-1101

LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC.

In
Rest of the answer

January 2012, we entered into an exclusive license agreement with LFB Biotechnologies, GTC Biotherapeutics, and LFB/GTC LLC, all wholly-owned subsidiaries of LFB Group, relating to the development of ublituximab. Under the license agreement, we have acquired the exclusive worldwide rights (exclusive of France/Belgium) for the development and commercialization of TG-1101 (ublituximab). To date, we have made no payments to LFB Group and LFB Group is eligible to receive payments of up to an aggregate of approximately $31.0 million upon our successful achievement of certain clinical development, regulatory and sales milestones, in addition to royalty payments on net sales of ublituximab at a royalty rate that escalates from mid-single digits to high-single digits. The license will terminate on a country by country basis upon the expiration of the last licensed patent right or 15 years after the first commercial sale of a product in such country, unless the agreement is earlier terminated.

The Company proposes to amend its disclosure regarding the Company’s sublicense agreement with Ildong Pharmaceutical Co. Ltd.in the following manner (the revised language is in italics), but also believes that the termination provision has been sufficiently addressed in the last sentence below for the same reasons discussed above:

Ildong Pharmaceutical Co. Ltd.

In November 2012, we entered into an exclusive (within the territory) sublicense agreement with Ildong Pharmaceutical Co. Ltd, (“Ildong”) relating to the development and commercialization of ublituximab in South Korea and Southeast Asia. Under the terms of the sublicense agreement, Ildong has been granted a royalty bearing, exclusive right, including the right to grant sublicenses, to develop and commercialize ublituximab in South Korea, Taiwan,

Singapore, Indonesia, Malaysia, Thailand, Philippines, Vietnam, and Myanmar. To date, we have received $2 million in the form of an upfront payment from Ildong, and are eligible to receive sales based milestone payments up to an aggregate of $5 million and royalty payments on net sales of ublituximab at a royalty rate that escalates from mid-teens to high-teens upon approval in South Korea and/or Southeast Asia. The license will terminate on a country by country basis upon the expiration of the last licensed patent right or 15 years after the first commercial sale of a product in such country, unless the agreement is earlier terminated.

collaboration agreement with Rhizen Pharmaceuticals, S.A. in the following manner (the revised language is in italics), but notes that the royalty rate has not yet been determined pursuant to Section 13.6(a) of the collaboration agreement, filed as Exhibit

10.1 to the Company’s Form 10-Q for the quarterly period ended September 30, 2012, filed on November 14, 2012:

TGR-1202

Rhizen Pharmaceuticals, S.A.

On August 15, 2012, the Company and Rhizen Pharmaceuticals S

A (“Rhizen”) entered into an exclusive global agreement to collaborate on the development and commercialization of

Rhizen’s lead product candidate (the “Collaboration Agreement”), a novel P13K delta inhibitor, (“TGR-1202”)

(previously referred to as RP5264). The companies will jointly develop the product on a worldwide basis, excluding India, initially focusing on indications in the area of hematologic malignancies and autoimmune disease. Beyond TGR-1202, Rhizen would contribute backup molecules providing multiple opportunities for TG to develop differentiated therapies against hematologic cancers and autoimmune diseases.

The Company will make up-front licensing payments and milestones based on early clinical development, and will be responsible for the costs of clinical development of the product through Phase

II, after which the Company and Rhizen will be jointly responsible for all development costs of the product. The Company and Rhizen will each maintain an exclusive option, exercisable at specific times during development, for the Company to license the rights to TGR-1202, in which case Rhizen would be eligible to receive upfront, development, and commercialization milestone payments in addition to milestone payments and royalties tied to net sales of the product, the aggregate of which could exceed $250 million.

Rhizen shall maintain rights to manufacture and supply the product to the Company, and the Company will be responsible for all clinical and regulatory development for TGR-1202 globally.

In connection with the Collaboration Agreement, to date we have paid an aggregate of $1,000,000 to Rhizen, and Rhizen is eligible to receive additional payments of up to $2,000,000 upon the successful achievement of certain clinical development milestones prior to entering profit and loss sharing for the TGR-1202 development program.

Pursuant to the terms of the Collaboration Agreement, should either of the exclusive license options be exercised, Rhizen would be eligible to receive up to an aggregate of $182.5 million upon the successful achievement of certain clinical development, regulatory, and sales based milestones in addition to royalties on net sales of TGR-1202. The Collaboration Agreement will terminate upon the earlier to occur of (i) the Company’s exercise of its license option, (ii) Rhizen’s exercise of its license option or (iii) the later to occur of (A) the expiration of the last applicable patent of the joint patents of the parties, Rhizen’s patents or the Company’s patents, or (B) the expiry of any other exclusivity right with respect to the product in a country, including patent term extensions, marketing exclusivity or any other non-patent exclusivity.

The Company acknowledges that it is responsible for the adequacy and accuracy of the disclosures in the 10-K, that staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the 10-K and that the Company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United

States.

If you have any further questions, comments or informational requests relating to this matter, please do not hesitate to contact me at the telephone number above.

Read in the reply
In its next report

First report after the company's reply of Oct 1, 2013: 10-Q filed Nov 14, 2013 ↗, against the 10-Q filed Aug 9, 2013 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Intellectual Property and Patents, page 8
SEC asked (1)
We note your response to our prior comment 1. However, we also note your disclosure that you have obtained commercial rights to a “series of patents” in addition to certain patent applications under the collaboration agreement with Rhizen. Please revise your proposed disclosure to clarify the expected expiration date of the “series of patents” licensed to you under your collaboration agreement.
Rest of the question

In the alternative, if the agreement did not provide you with license to a series of issued patents in addition to patent applications, please revise your disclosure to clarify that you do not currently have any issued patents in relation to TGR-1202.

TGTX answered
The Company proposes to revise its disclosure in the following manner:

Atlanta

•

Brussels

Charlotte

Dallas

Los

Angeles

New York

Research Triangle

Silicon

Valley

Ventura County

Washington, D.C.

Pursuant to our Collaboration Agreement with Rhizen Pharmaceuticals for TGR-1202, we have the exclusive commercial rights to a series of patent applications in the U.S.

and abroad.
Rest of the answer

The patent applications include a composition of matter patent relating to the genus of TGR-1202 and various backup compounds in addition to method of use patents which cover use of TGR-1202 in combination with various agents and for various therapeutic indications. All patent applications currently filed for TGR-1202 are currently pending. Because any potential date for regulatory approval is currently unknown we cannot predict the expected expiration date of the patents under application, and it is possible that the life of these patents following regulatory approval will be minimal.

Read in the reply
In its next report

First report after the company's reply of Nov 7, 2013: 10-Q filed Nov 14, 2013 ↗, against the 10-Q filed Aug 9, 2013 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Licensing Agreements and Collaborations, page 10
SEC asked (2)
We note your response to our prior comment 2. Our request for information in relation to termination provisions in the prior comment relates to the circumstances in which the respective agreements may be terminated prior to the end of their contractual term by the parties to the agreements.
Rest of the question

Please revise your proposed disclosure with respect to the license, sublicense, and collaboration agreements to describe the circumstances in which they may be “earlier terminated” under the terms of the agreements.

TGTX answered
The Company proposes further revisions to its disclosure regarding the Company’s license agreement with LFB Biotechnologies, GTC Biotherapeutics, and LFB/GTC LLC in the following manner:

TG-1101

LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC.

In January 2012, we entered into an exclusive license agreement with LFB Biotechnologies, GTC Biotherapeutics, and LFB/GTC LLC, all wholly-owned subsidiaries of LFB Group, relating to the development of ublituximab.
Rest of the answer

Under the license agreement, we have acquired the exclusive worldwide rights (exclusive of France/Belgium) for the development and commercialization of TG-1101 (ublituximab). To date, we have made no payments to LFB Group and LFB Group is eligible to receive payments of up to an aggregate of approximately $31.0 million upon our successful achievement of certain clinical development, regulatory and sales milestones, in addition to royalty payments on net sales of ublituximab at a royalty rate that escalates from mid-single digits to high-single digits. The license will terminate on a country by country basis upon the expiration of the last licensed patent right or 15 years after the first commercial sale of a product in such country, unless the agreement is earlier terminated (i) by LFB if the Company challenges any of the licensed patent rights, (ii) by either party due a breach of the agreement, or (iii) by either party in the event of the insolvency of the other party.

regarding the Company’s sublicense agreement with Ildong Pharmaceutical Co. Ltd.in the following manner:

Ildong Pharmaceutical Co. Ltd.

In November 2012, we entered into an exclusive

(within the territory) sublicense agreement with Ildong Pharmaceutical Co. Ltd, (“Ildong”) relating to the development and commercialization of ublituximab in South Korea and Southeast Asia. Under the terms of the sublicense agreement, Ildong has been granted a royalty bearing, exclusive right, including the right to grant sublicenses, to develop and commercialize ublituximab in South Korea, Taiwan, Singapore, Indonesia, Malaysia, Thailand, Philippines, Vietnam, and Myanmar. To date, we have received

$2 million in the form of an upfront payment from Ildong, and are eligible to receive sales based milestone payments up to an aggregate of $5 million and royalty payments on net sales of ublituximab at a royalty rate that escalates from mid-teens to high-teens upon approval in South Korea and/or Southeast Asia. The license will terminate on a country by country basis upon the expiration of the last licensed patent right or 15 years after the first commercial sale of a product in such country, unless the agreement is earlier terminated (i) by Ildong if the Company challenges any of the licensed patent rights, (ii) by either party due a breach of the agreement, or (iii) by either party in the event of the insolvency of the other party.

regarding the Company’s collaboration agreement with Rhizen Pharmaceuticals, S.A. in the following manner:

TGR-1202

Rhizen Pharmaceuticals, S.A.

On August 15, 2012, the Company and Rhizen

Pharmaceuticals S A (“Rhizen”) entered into an exclusive global agreement to collaborate on the development and commercialization of Rhizen’s lead product candidate (the “Collaboration Agreement”), a novel P13K delta inhibitor, (“TGR-1202”)

(previously referred to as RP5264). The companies will jointly develop the product on a worldwide basis, excluding India, initially focusing on indications in the area of hematologic malignancies and autoimmune disease. Beyond TGR-1202, Rhizen would contribute backup molecules providing multiple opportunities for TG to develop differentiated therapies against hematologic cancers and autoimmune diseases.

The Company will make up-front licensing payments and milestones based on early clinical development, and will be responsible for the costs of clinical development of the product through Phase II, after which the Company and Rhizen will be jointly responsible for all development costs of the product.

The Company and Rhizen will each maintain an exclusive option, exercisable at specific times during development, for the Company to license the rights to TGR-1202, in which case Rhizen would be eligible to receive upfront, development, and commercialization milestone payments in addition to milestone payments and royalties tied to net sales of the product, the aggregate of which could exceed $250 million. Rhizen shall maintain rights to manufacture and supply the product to the Company, and the Company will be responsible for all clinical and regulatory development for TGR-1202 globally.

In connection with the Collaboration Agreement, to date we have paid an aggregate of $1,000,000 to Rhizen, and Rhizen is eligible to receive additional payments of up to $2,000,000 upon the successful achievement of certain clinical development milestones prior to entering profit and loss sharing for the TGR-1202 development program. Pursuant to the terms of the Collaboration Agreement, should either of the exclusive license options be exercised, Rhizen would be eligible to receive up to an aggregate of $182.5 million upon the successful achievement of certain clinical development, regulatory, and sales based milestones in addition to royalties on net sales of TGR-1202. The Collaboration

Agreement will terminate upon the earlier to occur of (i) the Company’s exercise of its license option, (ii) Rhizen’s exercise of its license option or (iii) the later to occur of (A) the expiration of the last applicable patent of the joint patents of the parties, Rhizen’s patents or the Company’s patents, or (B) the expiry of any other exclusivity right with respect to the product in a country, including patent term extensions, marketing exclusivity or any other non-patent exclusivity. In addition, the agreement may be earlier terminated (i) by the Company with or without cause upon six months’ notice, (ii) by either party due to a breach of the agreement by the other party, (iii) by either party upon the insolvency of the other party, or (iv) by Rhizen if, even when conditions are met, the Company still fails to file a new drug application. In case of a termination pursuant to (i), (ii) or (iv) in the preceding sentence, Rhizen has the right to obtain a license to the Company’s intellectual property relating to TGR-1202, for a royalty rate to be equal to the current fair market value of the license to be negotiated by the parties at the time of termination.

Read in the reply
In its next report

First report after the company's reply of Nov 7, 2013: 10-Q filed Nov 14, 2013 ↗, against the 10-Q filed Aug 9, 2013 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Licensing Agreements and Collaborations, page 10
SEC asked (3)
Please revise your proposed disclosure with respect to the collaboration agreement with Rhizen to describe the circumstances in which Rhizen would be obligated to make royalty payments to the Company as indicated in Section 13.6(a) of the agreement.
TGTX answered
The last sentence of the disclosure of the

Rhizen agreement above is the disclosure we suggest in response to this comment.

The Company acknowledges that it is responsible for the adequacy and accuracy of the disclosures in the 10-K, that staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the 10-K and that the Company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United

States.

If you have any further
Rest of the answer

questions, comments or informational requests relating to this matter, please do not hesitate to contact me at the telephone number above.

Read in the reply
In its next report

First report after the company's reply of Nov 7, 2013: 10-Q filed Nov 14, 2013 ↗, against the 10-Q filed Aug 9, 2013 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2013-11-20

Form S-3

2013-06-05 to 2013-06-17 · 1 question · 1 letter from the SEC, 2 from the company
No closing letter
General
SEC asked
We note that that you have a pending confidential treatment request. Please be advised that we will not be in a position to accelerate the effectiveness of your registration statement until we have completed processing your confidential treatment request.
TGTX answered
(the “Company”), hereby requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 11:00 a.m. (ET) on June 17, 2013 or as soon as practicable thereafter, pursuant to Rule

461 of the Securities Act of 1933, as amended.

The Company acknowledges that (i) should the Commission or the staff of the Commission, acting pursuant to delegated authority, declare the filing effective, such declaration does not foreclose the Commission from taking any action with respect to the filing; (ii) the action of the Commission or the
Rest of the answer

staff of the Commission, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the

Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and (iii) the Company may not assert the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Read in the reply

Also in this review: company letter, Jun 17, 2013

Schedule 14A

2011-03-08 to 2011-03-21 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2011-03-21
SEC asked
Please amend your filing to include disclosure that clearly states the number of shares of common stock that may be issued in connection with the “Nordic Settlement” on a pre and post split basis.
TGTX answered
In response to the Staff’s comment, please note that no shares of common stock are to be issued with respect to the “Nordic Settlement.” We propose to revise the disclosure on page 27 of the above-referenced filing as follows to clarify that point and to reflect the receipt of the $400,000 payment referred to in the fourth bullet point (which was received after we filed the preliminary proxy statement):

The Nordic Settlement

On January 4, 2011 we entered into settlement and release agreement (the “Settlement and Release Agreement”) with Nordic Biotech Venture Fund II K/S (“Nordic”) and H
Rest of the answer

Pharmaceuticals K/S (the "Joint Venture"). Nordic and us are partners in the Joint Venture for the development and commercialization in North America of Hedrin™, a non-pesticide, one-hour, treatment for pediculosis (head lice). As previously reported, Nordic and us have had various disputes relating to the Joint Venture and to Nordic’s option to purchase our common stock in exchange for a portion of Nordic’s interest in the Joint Venture (the "Put Right"), and Nordic’s warrant to purchase our common stock (the "Warrant”). The Settlement and Release

Agreement resolved all disputes between Manhattan, on the one hand, and Nordic and the Joint Venture, on the other.

The principal terms of the Settlement and Release Agreement are:

·

No shares of our common stock will be issued to Nordic.

The Put Right has been terminated. We believed the Put Right permitted Nordic to become the owner, upon exercise of the Put Right, of 71,428,571 shares of our common stock. Nordic asserted that the Put Right would have permitted Nordic to become the owner of 183,333,333 shares of our common stock.

The Warrant has been terminated. We believed the Warrant covered 14,285,714 shares of our common stock. Nordic asserted that the Warrant covered 33,333,333 shares of our common stock.

Nordic was required to make an additional, non-dilutive capital contribution to the Joint Venture of $1,500,000, which includes $300,000 contributed to the Joint Venture by Nordic on December 15, 2010.

The Joint Venture has paid will pay to us a settlement amount of $500,000, less any "Excess Payment" (defined below), in two installments. The first installment of $100,000 is due within five (5) business days of the execution of the Settlement and Release Agreement and the second installment of $400,000 is due within five (5) business days after we have received written evidence that the holders of our 12% Secured Notes, $1,315,000 of which has matured and is now past due, have either converted the 12%

Secured Notes into shares of equity securities of us prior to December 31, 2011or agreed to extend the maturity of the 12% Secured Notes to December 31, 2011 by such date. An "Excess Payment" is the amount by which Nordic’s and the Joint Venture’s reasonable out-of-pocket legal and other costs incurred with respect to the Settlement and Release Agreement, including any challenge to the enforceability of the Settlement and Release Agreement, including in a bankruptcy proceeding, exceed $70,000. To date there have been no Excess Payments.

Our equity interest in the Joint Venture is reduced to 15%, and further reductions in our equity interest are possible if and when Nordic makes additional capital contributions to the Joint Venture. In no event shall capital contributions by Nordic reduce our ownership in the Joint Venture below 5%.

The Joint Venture paid will pay $75,000 to us under the Services Agreement, dated February 21, 2008, and that Services Agreement is terminated.

The Joint Venture Agreement, dated January 31, 2008, as amended on February 18, 2008, and as further amended by an Omnibus Amendment on June 9, 2008, between Manhattan and Nordic; the Shareholders’ Agreement, dated February 21, 2008, as amended by an Omnibus Amendment on June 9, 2008, with respect to the Joint Venture, and the Registration Rights Agreement, dated February 25, 2009, are terminated.

The Limited Partnership Agreement, dated February 21, 2008, as amended by an Ominibus Amendment on June 9, 2008, with respect to the Joint Venture, has been consolidated and amended on the terms described above to include some of the terms described above. In addition, under the new consolidated and amended limited partnership agreement, we have no right to participate in the management of the Joint Venture or its Hedrin assets and limited rights of a minority Partner.

Messrs. Michael G. McGuinness and Douglas Abel resigned from the Board of Directors of the Joint Venture.

As requested in your comment letter, the Company hereby acknowledges that:

the Company is responsible for the adequacy and accuracy of the disclosure in the filing referred to herein;

Staff comments or changes in disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filings; and the Company may not assert Staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

If you should have any questions concerning the enclosed matters, please do not hesitate to call me at (212) 492-8741.

Read in the reply

Also in this review: closing letter, 2011-03-21

Form 10-K for the Fiscal Year Ended December 31, 2008

2009-12-29 to 2010-01-12 · 3 questions · 1 letter from the SEC, 1 from the company
No closing letter
Controls
Item 9A(T). Controls and Procedures, page 52
SEC asked (1)
Your CEO and CFO concluded that the “disclosure controls and procedures were effective as of that date in alerting them on a timely basis” to information that is required to be disclosed. Your interim Forms 10-Q contain similar language. This conclusion does not appear to satisfy Item 307 of Regulation S-K and Rule 13a-15(e) under the Exchange Act.
Rest of the question

Rule 13a-15(e) states that disclosure controls and procedures should ensure that information required to be disclosed “is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms.” Please confirm that the disclosure controls and procedures ensure that information required to be disclosed is recorded, processed, summarized and reported within the time periods specified in the Commission’s rules and procedures. If you are unable to confirm this statement, • Please provide further explanation including a description of any weaknesses that prevented the CEO and CFO from concluding that the disclosure controls and procedures were effective; and • Amend the Form 10-K to describe the weaknesses.

TGTX answered
The

Company confirms that its disclosure controls and procedures were effective at the reasonable assurance level to ensure that information required to be disclosed by the issuer in the reports that it files or submits under the

Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission's rules and forms.
Rest of the answer

The Company will conform its disclosure in future SEC filings to disclose whether its disclosure controls and procedures are effective at the reasonable assurance level to ensure that information required to be disclosed by the issuer in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission's rules and forms.

Read in the reply
In its next report

First report after the company's reply of Jan 12, 2010: 10-K filed Mar 31, 2010 ↗, against the 10-K filed Mar 31, 2009 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Item 9A(T). Controls and Procedures, page 52
SEC asked (2)
It is not clear what the intent is of your disclosure in the second paragraph: “There can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.” Please revise to clarify that the disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives.
Rest of the question

In addition, please revise to state, if true, that the controls and procedures are, in fact, effective at the “reasonable assurance” level. Please refer to Section II.F.4 of Management’s Reports on Internal Control Over Financial Reporting and Certification of Disclosure in Exchange Act Periodic Reports, SEC Release No. 33-8238, available on our website at <http://www.sec.gov/rules/final/33-8238.htm>.

TGTX answered
intent of the Company’s disclosure was to convey that disclosure controls and procedures no matter how well designed can provide only reasonable, not absolute, assurance of achieving its objectives. The

Company confirms that its disclosure controls and procedures were effective at the reasonable assurance level to ensure that information required to be disclosed by the issuer in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission's rules and forms.
Rest of the answer

The Company acknowledges the staff’s comments and will revise its disclosure to clarify that its disclosure controls and procedures are designed to provide only reasonable assurance that such disclosure controls and procedures will achieve their objectives in its upcoming annual report on Form 10-K. In addition, the Company will present the conclusions of its executive officers as to whether its disclosure controls and procedures are effective at the reasonable assurance level.

Read in the reply
In its next report

First report after the company's reply of Jan 12, 2010: 10-K filed Mar 31, 2010 ↗, against the 10-K filed Mar 31, 2009 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Exhibits 31.1 and 31.2
SEC asked (3)
Please tell us why your executive certifications do not include the entire introductory language of paragraph 4 of Item 601(b)(31) of Regulation S-K to also address your officers’ responsibility for establishing and maintaining internal control over financial reporting. This comment also applies to the certifications filed for the quarterly periods ended March 31, 2009, June 30, 2009 and September 30, 2009.
Rest of the question

* * * * Please provide us the information request ed within 10 business days or tell us when you will provide us with a response. Please furnish a cover letter with your response that keys your response to our comments. Detailed cover letters greatly facilitate our review. Please furnish your letter on EDGAR under the form type label CORRESP.

TGTX answered
Company inadvertently omitted the phrase "and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))" from its executive certifications filed with its annual report on Form 10-K and its quarterly reports on Form 10-Q for the periods ended March 31, 2009, June 30,

2009 and September 30, 2009. Such omission was unintentional.
Rest of the answer

The Company confirms that its executive officers are responsible for establishing and maintaining disclosure controls and procedures

(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and

15d-15(f)) for the registrant. The Company acknowledges the Staff's comments and will include the phrase "and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))" in its executive certificates in future filings.

*******

Company acknowledges that:

• the

Company is responsible for the adequacy and accuracy of the disclosure in the filing;

• Staff comments or changes to disclosure in response to Staff comments do not foreclose the Commission from taking any action with respect to the filing;

Company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United

States.

call me at 212-492-8741 if there are any questions or further information is required.

Read in the reply
In its next report

First report after the company's reply of Jan 12, 2010: 10-K filed Mar 31, 2010 ↗, against the 10-K filed Mar 31, 2009 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Schedule 14A

2009-10-08 to 2009-10-28 · 2 questions · 1 letter from the SEC, 1 from the company
Review closed 2009-10-28
SEC asked (1)
Please revise your disclosure to include all of the information that would be required if your shareholders were voting on the merger, including the information required by Item 14 of Schedule 14A. Refer to Note A to Schedule 14A for further guidance.
TGTX answered
to the Comment Letter, the Company has considered the application of

Note A to Schedule 14A and has concluded that the proposal to approve the amendment to the Company's charter to increase the number of authorized shares of common stock is not also a solicitation with respect to the consummation of the acquisition of Ariston Corporation described in the preliminary proxy statement (the "Ariston Acquisition") or the financing upon which closing of the

Ariston Acquisition is conditioned.
Rest of the answer

Further, the Company's securities trade on the Over the Counter Bulletin Board ("OTC") and therefore the Company would not be subject to any shareholder approval requirements under any exchange listing rules. Unlike other situations where the vote on the proposal being submitted to stockholders could affect whether or not the transactions are consummated, the Company could and would consummate the Ariston Acquisition and the financing transaction even if the stockholders rejected the proposal to amend the Company's certificate of incorporation to increase the number of authorized shares of Company common stock. The Ariston Acquisition is not conditioned upon an increase of authorized shares of Company common stock.

As of

October 19, 2009, as illustrated in the chart below, the Company had 80,167,681 shares of common stock which were authorized and available for future issuance.

October

19,

2009

Shares of Common Stock authorized

300,000,000 of Common Stock issued and outstanding

70,624,232 of Common Stock reserved for issuance under option plans

7,592,436 of Common Stock reserved for issuance pursuant to outstanding warrants

86,060,096 of Common Stock reserved for put and call rights

55,555,555 of Common Stock available for future issuance

80,167,681

As set forth in the executed term sheet between the Company and Ariston, the maximum number of shares of Company common stock issuable to Ariston stockholders pursuant to the Ariston Acquisition is 31,780,904 (24,718,481 of which shares are contingent upon achievement of post-closing milestones).

Assuming the issuance of all 31,780,904 shares of Company common stock pursuant to the

Ariston Acquisition, the Company would still have 48,386,777 shares of authorized common stock available for future issuance.

addition, the Company may issue shares of common stock in connection with a $2.5 million debt or equity financing transaction which is a condition precedent to the consummation of the Ariston Acquisition. The Company has not engaged a financial advisor to assist it in that financing, and, to date, there are no specific plans for such financing. The Company has not identified an investor, nor negotiated the terms of such a financing transaction. Therefore, at this time, it is not possible to determine the exact number of shares of Company common stock that may be issued in the future in connection with such financing. However, the Company anticipates that it may need to issue (or reserve for issuance) between

16,000,000 and 28,000,000 shares of its common stock in connection with such financing, which is well within the 48,386,777 shares of common stock which would be available for future issuance after giving effect to the shares reserved for issuance in connection with the Ariston Acquisition.

Following the Ariston Acquisition, Ariston (which would then be a subsidiary of the

Company) would continue to be the obligor under $15.5 million in aggregate principal amount of convertible promissory notes. The Company and

Ariston expect to renegotiate the terms of those convertible promissory notes, and if sufficient authorized shares of Company common stock are available, to have those notes become convertible into shares of Company common stock at a conversion price of $0.40 per share (a conversion price that would be 500% of the current market price as of October 20, 2009). However, having additional authorized shares of Company common stock available for Ariston note conversion is not a condition precedent to the Ariston Acquisition.

Company will revise the disclosure in the Proxy Statement to clarify that while the Company can consummate both the Ariston Acquisition and the related (but as-yet-undefined) $2.5 million financing, the Company is proposing the amendment to the Company's certificate of incorporation to increase the authorized shares of common stock to give the Company flexibility to fund future growth of the

Company and for other as-yet undetermined needs.

Accordingly, while the Company believes that it has, and intends to, provide all material information pursuant to Items 11 and 13 of Schedule 14A, it does not believe that it needs to provide information required by Item 14 of Schedule 14A as Note

A to Schedule 14A is not applicable with respect to the Ariston

Acquisition.

Read in the reply
SEC asked (2)
Please expand your disclosure to include a discussion of the currently authorized and unissued shares that will become available for issuance if Proposals 1 and 4 are approved; and discuss and plans to issue these shares aside from the merger. * * * As appropriate, please amend your filing and respond to these comments within 10 business days or tell us when you will provide us with a response.
Rest of the question

You may wish to provide us with marked copies of the amendment to expedite our review. Please furnish a cover letter with your amendment that keys your responses to our comments and provides any requested information. Detailed cover letters greatly facilitate our review. Please understand that we may have additional comments after reviewing your amendment and responses to our comments.

TGTX answered
In the interests of efficiency and to avoid potentially confusing disclosure, the

Company has decided to withdraw its proposal to authorize its Board of

Directors, at their discretion, to amend the Company's Certificate of

Incorporation to implement a reverse stock split of its issued and outstanding shares of common stock.
Rest of the answer

The Company will amend its preliminary proxy statement to remove such proposal.

* * *

This will confirm that the Company understands that:

· the

Company is responsible for the adequacy and accuracy of the disclosure in the filing; staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and

Company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Read in the reply

Also in this review: closing letter, 2009-10-28

Form S-1

2009-03-11 to 2009-03-11 · 3 questions · 1 letter from the SEC, 0 from the company
No closing letter
Executive pay
SEC letter of Mar 11, 2009 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
General
SEC asked (1)
Please provide updated financial statements and financial information throughout the filing pursuant to Rule 3-01 of Regulation S-X.
TGTX answered

No reply letter found.

General
SEC asked (2)
Please update your registration statement to disclose the executive compensation information for fiscal year 2008.
TGTX answered

No reply letter found.

Pending Financial Statement Waiver Request
SEC asked (3)
It appears that the Company has a pending request for financial statement waiver in connection with an application filed June 18, 2008. Please be advised that we will not be in a position to consider a request for acceleration of effectiveness of the registration statement until we resolve all issues concerning the financial statement waiver request.
Rest of the question

* * * As appropriate, please amend your regist ration statement in response to these comments. You may wish to provide us with marked copies of the amendment to expedite our review. Please furnish a cover letter with your amendment that keys your responses to our comments and provides any requested information. Detailed cover letters greatly facilitate our review. Please understand that we may have additional comments after reviewing your amendment and responses to our comments.

TGTX answered

No reply letter found.

Form S-1

2008-05-13 to 2008-06-09 · 4 questions · 2 letters from the SEC, 1 from the company
No closing letter
Legal and contingencies
General
SEC asked
We note that you are proposing to register the resale of up to 17,857,143 shares of common stock that may be issued in connection with the put or call rights and up to 17,857,143 additional shares which may become issuable. Based on your disclosures in the registration statement, it appears that these securities are not outstanding and are subject to a further investment decision by the selling shareholder.
Rest of the question

Therefore, it appears that you cannot register their resale at this time. Please revise your registration statement to remove these shares. If you disagree, please supplementally provide us with a detailed analysis which supports your apparent conclusion that these shares being registered for resale should be considered outstanding and that it is not premature to register their resale at this time. As appropriate, please amend your registration statement in response to these comments. You may wish to provide us with marked copies of the amendment to expedite our review. Please furnish a cover letter with your amendment that keys your responses to our comments and provides any requested information. Detailed cover letters greatly facilitate our review. Please understand that we may have additional comments after reviewing your amendment and responses to our comments. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes all information required under the Securities Act of 1933 and that they have provided all information investors require for an informed investment decision. Since the company and its management are in possession of all facts relating to a company’s disclosure, they are responsible for the accuracy and adequacy of the disclosures they have made. Notwithstanding our comments, in the event the company requests acceleration of the effective date of the pending registration statement, it should furnish a letter, at the time of such request, acknowledging that: ‚ should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; ‚ the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and ‚ the company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. In addition, please be advi sed that the Division of Enforcement has access to all information you provide to the staff of the Division of Corporation Finance in connection with our review of your filing or in response to our comments on your filing. We will consider a written request for acceleration of the effective date of the registration statement as confirmation of the fact that those requesting acceleration are aware of their respective responsibilities under the Securities Act of 1933 and the Securities Exchange Act of 1934 as they relate to the proposed public offering of the securities specified in the above registration statement. We will act on the request and, pursuant to delegated authority, grant acceleration of the effective date. We direct your attention to Rules 460 and 461 regarding requesting acceleration of a registration statement. Please allow adequate time after the filing of any amendment for further review before submitting a request for acceleration. Please provide this request at least two business days in advance of the requested effective date.

TGTX answered

No numbered answer found in the reply. Read the reply ↗

SEC letter of Jun 9, 2008 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
General
SEC asked (1)
It appears that you have not filed copies of all of the exhibits to the joint venture agreement. Please be aware that when you file an agreement pursuant to Item 601(b)(10) of Regulation S-K, you are required to file the entire agreement, including all exhibits, schedules, appendices and any document which is incorporated in the agreement.
Rest of the question

Please amend your registration statement to provide a copy of the full and complete joint venture agreement, including any exhibits, schedules and appendices which are included in the agreement. We may have further comments upon reviewing the full and complete agreement.

TGTX answered

No reply letter found.

General
SEC asked (2)
In connection with the put right, please revise your registration statement throughout to register only the resale of up to 17,857,143 shares underlying the put of Nordic’s current investment in the joint venture which appears to be $2.5 million.
Rest of the question

Given the contingency regarding FDA approval occurring as to the second $2.5 million investment by Nordic in the joint venture, and that the put right as to those shares does not currently and may never actually exist, it is premature to register the resale of shares underlying that put right.

TGTX answered

No reply letter found.

General
SEC asked (3)
In connection with the call right, we note that Nordic has the right to refuse the call and pay a cash amount to you. Since the call right provides that Nordic has a decision to either pay cash or exchange its interest in the joint venture for shares of your common stock, it appears that the registration of the common shares underlying the call option is premature.
Rest of the question

Please amend your registration statement to remove these shares. As appropriate, please amend your regist ration statement in response to these comments. You may wish to provide us with marked copies of the amendment to expedite our review. Please furnish a cover letter with your amendment that keys your responses to our comments and provides any requested information. Detailed cover letters greatly facilitate our review. Please understand that we may have additional comments after reviewing your amendment and responses to our comments. We direct your attention to Rules 460 and 461 regarding requesting acceleration of a registration statement. Please allow adequate time after the filing of any amendment for further review before submitting a request for acceleration. Please provide this request at least two business days in advance of the requested effective date.

TGTX answered

No reply letter found.

Form 10-QSB

2006-11-07 to 2007-01-10 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2007-01-10
Results discussion (MD&A)
Management’s Discussion and Analysis of Financial Condition and Results of Operations
SEC asked
Please provide us information in disclosure-type format describing: • Your accounting policy for recording research and development expenses for the clinical study provided by Swiss Pharma in order to clarify what you mean by “on an activity basis;” • What the initial payment of 20% upon signing the agreement represents and your accounting treatment for this and each other payment; • How you measure and monitor the
Rest of the question

services performed by Swiss Pharma; and, • The termination provisions under the contract. Please provide us the information requested within 10 business days of the date of this letter or tell us when you will provide a response prior to the expiration of the 10-day period. Please furnish a letter with your response that keys your response to our comment. Detailed letters greatly facilitate our review. You should furnish the letter to us via EDGAR under the form type label CORRESP.

TGTX answered
In response to your comment, the Company intends to include the following disclosure of its agreement with Swiss Pharma in the appropriate places of its reports filed with the Commission, including in its footnote disclosures accompanying its financial statements:

Company often contracts with third parties to facilitate, coordinate and perform agreed upon research and development of drug product candidates.
Rest of the answer

To ensure that research and development costs are expensed as incurred, the Company records monthly accruals for clinical trials and preclinical testing costs based on work performed under the contracts.

These contracts typically call for the payment of fees for services at the initiation of the contract and/or upon the achievement of certain milestones. This method of payment often does not match the related expense recognition resulting in either a prepayment, when the amounts paid are greater than the related research and development costs recognized, or an accrued liability, when the amounts paid are less than the related research and development costs recognized.

Because expenses associated with the ongoing clinical trials are recognized on this activity based basis, the Company’s expense recognition differs from the payment schedules.

On

March

27, 2006, the Company entered into a research and development agreement with

Swiss Pharma Contract Ltd. (“Swiss Pharma”) to perform a Phase IIa study of the

Company’s Oleoyl-estrone product for the treatment of obesity. The terms of the agreement call for the Company to pay Swiss Pharma up to $2,151,840 for the completion of the Phase IIa study in accordance with the terms of the contract.

The payment terms are: 20%, or $430,368, upon signing the agreement, 20% after the first patient has received the initial dose, 20% after half patients have received the initial dose, 20% after all patients have completed dosing, 10%, on receipt of statistical analyses and 10% on acceptance by the

Company of the Phase IIa study.

agreement with Swiss Pharma provides for conducting a Phase IIa study in 100 patients and contains a detailed description of the services to be performed, as well as a related list of fees to be charged by Swiss Pharma for the provision of specific services under the agreement. The maximum fees payable under the agreement are $2,151,840. In order for Swiss Pharma to earn the maximum amount of $2,151,840, it must complete the Phase IIa study in 100 patients and perform all of the ancillary services detailed in the contract. If Swiss Pharma carries out the Phase IIa study on less than 100 patients or if it does not complete all of the ancillary services detailed in the agreement, the Company will be obligated to pay an amount less than the $2,151,840. Such lesser amount would determined by applying the services performed to the related list of fees to charged as detailed in the agreement.

Company recognizes expense under the contract as the specific services are performed by Swiss Pharma. Swiss Pharma provides the Company with an activity report on a weekly basis on which the Company bases its activity based expense recognition. As of September 30, 2006, the Company had paid Swiss Pharma

$860,736, and recognized $243,777 of research and development expense for the

Phase IIa study. The remainder, $616,959, is included in prepaid expenses.

agreement with Swiss Pharma may be terminated by the Company for any reason, in which case the Company would be liable to Swiss Pharma for all fees, as described in the agreement, associated with the services performed as of the termination date and services performed after the termination date to effect an orderly wind-down of the study. The agreement provides that Swiss Pharma shall return to the Company any funds paid by the Company, but not earned by Swiss

Pharma, upon termination of the contract.

*

* * *

Company acknowledges that it is responsible for the adequacy and accuracy of disclosure in the filings, that the staff comments or changes to disclosure response to staff comments do not foreclose the Commission from taking any action with respect to the filing, and the Company may not assert staff comments as a defense in any proceeding initiated by the Commission or any other person under the federal securities laws of the United States.

If have any questions or need additional information please contact me, my direct phone line is 212-492-8741 and my email address is [email protected]

Read in the reply

Also in this review: closing letter, 2007-01-10

Letters without questions

Other letters

UPLOAD and CORRESP
6 other letters: notices that a filing will not be reviewed, requests to declare a registration effective, and the like

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 31 letters filed since 2006-12-12. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/TGTX/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.